Amyris (NASDAQ:AMRS) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.02, Fidelity Earnings reports. The business had revenue of $34.95 million during the quarter, compared to the consensus estimate of $21.60 million.
Shares of Amyris stock traded up $0.54 during trading hours on Friday, reaching $4.52. The company’s stock had a trading volume of 2,224,200 shares, compared to its average volume of 1,905,229. The company’s 50 day simple moving average is $4.00 and its 200 day simple moving average is $3.88. The stock has a market cap of $431.70 million, a P/E ratio of -1.79 and a beta of 0.91. Amyris has a one year low of $1.87 and a one year high of $7.26.
A number of research analysts have recently issued reports on AMRS shares. BidaskClub upgraded shares of Amyris from a “sell” rating to a “hold” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Amyris in a research report on Friday, October 11th.
Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.
Further Reading: What economic reports are most valuable to investors?
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.